Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Smith, I. E.
Biganzoli, L.
Cortes-Funes, H.
Stroyakovskiy, D.
Franke, F. A.
Chlistalla, A.
Pierga, J-Y
Thomssen, C.
Pritchard, K.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Hosp Prato, Tuscany Canc Inst, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] City Clin Oncol Hosp, Moscow, Russia
[5] Hosp Caridade Ijui, Ijui, Brazil
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Inst Curie, Paris, France
[8] Univ Halle Wittenberg, Halle, Germany
[9] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：286S / 286S
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study
    Xu Bing-he
    Jiang Ze-fei
    Shen Zhen-zhou
    Guan Zhong-zhen
    Chen Zheng-dong
    Cheng Ying
    Zheng Hong
    Jiang Jun
    Wang Xiao-jia
    Tong Zhong-sheng
    Qin Shu-kui
    Luo Yi
    Yao Min
    Wang Li-wei
    He Jing
    CHINESE MEDICAL JOURNAL, 2012, 125 (05) : 764 - 769
  • [32] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: an open-label, multicenter phase II study.
    Song, HS
    Do, YR
    Chang, HM
    Lee, KH
    Kim, YH
    Hong, DS
    Cho, JY
    Lee, KE
    Kim, SY
    Ryu, MH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 343S - 343S
  • [33] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [34] Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
    Andre, Thierry
    Falcone, Alfredo
    Shparyk, Yaroslav
    Moiseenko, Fedor
    Polo-Marques, Eduardo
    Csoszi, Tibor
    Campos-Bragagnoli, Arinilda
    Liposits, Gabor
    Chmielowska, Ewa
    Aubel, Paul
    Martin, Lourdes
    Fougeray, Ronan
    Amellal, Nadia
    Saunders, Mark P.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (02): : 133 - 144
  • [35] BEVACIZUMAB-CAPECITABINE (BEV-CAP) AFTER INITIAL 1ST-LINE BEVACIZUMAB-DOCETAXEL (BEV-DOC) IN PATIENTS (PTS) WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC): SAFETY ANALYSIS OF THE IMELDA TRIAL
    Gligorov, J.
    Alba-Conejo, E.
    Bines, J.
    Cortes, P. A.
    Doval, D. C.
    Jiang, Z.
    Freudensprung, U.
    Mustacchi, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 128 - 128
  • [36] Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
    von Minckwitz, Gunter
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Marschner, Norbert
    Zielinski, Christoph
    Villanueva, Cristian
    Romieu, Gilles
    Lang, Istvan
    Ciruelos, Eva
    De laurentiis, Michele
    Veyret, Corinne
    de Ducla, Sabine
    Freudensprung, Ulrich
    Srock, Stefanie
    Gligorov, Joseph
    LANCET ONCOLOGY, 2014, 15 (11): : 1269 - 1278
  • [37] Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV plus docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC])
    Fumoleau, P.
    Greil, R.
    Rayson, D.
    Mueller, V
    Barni, S.
    Aleknavicius, E.
    Tellez, E.
    Wilson, C.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 104S - 104S
  • [38] Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: preliminary results from an open-label, multicenter phase II study
    Song, Hong Suk
    Do, Young Rok
    Chang, Heung Moon
    Ryu, Min Hee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Hong, Dae Sik
    Cho, Jae Yong
    Lee, Kyoung Eun
    Kim, Si Young
    ANNALS OF ONCOLOGY, 2004, 15 : 243 - 243
  • [39] Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin or capecitabine: A Phase Ill, open-label, randomized study
    Cortes, J.
    Awada, A.
    Kaufmann, P. A.
    Yelle, L.
    Perez, E. A.
    Velikova, G.
    Wanders, J.
    Olivo, M.
    He, Y.
    Ductus, C.
    Simons, R.
    Bischoff, J.
    Twelves, C.
    ONKOLOGIE, 2013, 36 : 97 - 97
  • [40] A randomized open-label, phase H study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients (pts) with ErbB2-amplified metastatic breast cancer (MBC) progressing after taxane treatment-GLICO-0801.
    Gomez, H. L.
    Neciosup, S. P.
    Neron do Nascimento, Y.
    Ismael, G.
    Barrios, C. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345